[Severe electrolyte imbalance and XXXX in therapy with @entity6170 ].

@entity1 @entity1007 @entity4 @entity2865 @entity409 @entity1372 @entity460 @entity972 @entity2827 @entity99 @entity6170
CASE REPORT: A case of a 49-year-old male with preexisting @entity409 is reported. The @entity1 was admitted to hospital with severe electrolyte disorder and face @entity4 after therapy first with 4 mg for 2 months and later for 5 months with 8 mg @entity6170 . The initial electrolyte values were: @entity1372 110 mmol/l, @entity972 3.3 mmol/l, @entity460 2.0 mmol/l, @entity2865 81 mmol/l. An already known @entity1007 worsened substantially to values up to 28.5 mmol/l. Under substitution therapy with @entity2827 infusion and @entity972 , the electrolyte level normalized rapidly. The @entity1007 improved over several weeks after stopping the drug, and the general condition of the @entity1 improved clearly. CONCLUSION: @entity6170 has been certified in Germany since July 2000. Although a @entity99 with @entity6170 has been denied, the administration of this drug in @entity1 with @entity409 is contraindicated. Especially when prescribing new drugs one has to pay special attention to contraindications and comedication since often not all therapeutic mechanisms and side effects are fully known/understood. Interaction between different drugs and their influences on existing diseases are only noticed after a widespread application of the drug.
